{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
Antibiotiki. Nov 1975;20(11):1029-32.: Not Applicable Human clinical trial Completed Candidiasis, Oral/microbiology
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01473056: Phase 1 Interventional Completed Hepatitis C Virus Infection, Response to Therapy of
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
JTK-853, a piperazine derivative, is a non-nucleoside inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase. It is under development for the treatment of hepatitis C virus infection.
Status:
Investigational
Source:
NCT03860506: Phase 1 Interventional Completed Healthy
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
PSI-697 is a quinoline derivative patented by Wyeth, John, and Brother Ltd. as a selectin inhibitor useful for the treatment of acute coronary syndromes. Surface expression of P-selectin on activated platelets induces the formation of platelet-monocyte aggregates and promotes vascular inflammation and thrombosis. In cell-based assays, PSI-697 dose-dependently inhibits the binding of human P-selectin to human P-selectin glycoprotein ligand-1. In preclinical trials, PSI-697, promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis. Animals receiving PSI-697 demonstrated significantly increased plasma D-dimer levels versus low-molecular-weight-heparin and control animals six hours post thrombus induction. Unfortunately, in clinical trials, PSI-697 did not inhibit basal or stimulated platelet-monocyte aggregate formation in humans
Status:
Investigational
Source:
NCT01573819: Phase 1 Interventional Completed Huntington Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
GlaxoSmithKline is developing GSK-356278 as a selective, brain-penetrant phosphodiesterase 4 (PDE4) inhibitor that demonstrates anxiolytic and cognition-enhancing effects. Small molecule phosphodiesterase (PDE) 4 inhibitors have long been known to show therapeutic benefit in various preclinical models of psychiatric and neurologic diseases because of their ability to elevate cAMP in various cell types of the central nervous system. The drug was studied for the treatment of Huntington's disease, depressive and anxiety disorders. GSK-356278 has completed phase I clinical trials for evaluation of the safety, tolerability, and pharmacokinetics in male volunteers with the therapeutic dose for future clinical development.
Status:
Investigational
Source:
NCT02499497: Phase 2 Interventional Completed Prostate Cancer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
LY2452473 is a selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activity. Upon oral administration, LY2452473 acts as an agonist in select tissues and organs, including skeletal muscle, bone and the penis, thereby binding to and activating androgen receptor (AR) while acting as an antagonist in the prostate, thereby blocking AR activation and AR-mediated cellular proliferation. This may improve muscle mass and strength, bone formation, and erectile dysfunction while not stimulating growth of the prostate. Eli Lilly was developing LY 2452473/tadalafil combination for the treatment of erectile dysfunction. In addition, Eli Lilly is studying the use of a targeted LY 2452473 therapy, as a possible improvement in quality of life for prostate cancer patients who have undergone radical prostatectomy.
Status:
Investigational
Source:
NCT04173065: Phase 2 Interventional Completed NASH - Nonalcoholic Steatohepatitis
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
MB-07811 (VK-2809) is the liver-activated prodrug of a phosphonate-containing thyroid hormone receptor beta agonist MB-07344. In animal studies, it showed potent lipid and cholesterol lowering activity. Viking Therapeutics is developing MB-07811 hypercholesterolaemia and non-alcoholic fatty liver disease.
Status:
Investigational
Source:
NCT00258622: Phase 2 Interventional Completed Pain
(2005)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
NCT02573870: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Batefenterol, previously known as GSK961081, a bifunctional muscarinic (M2 and M3 receptors) antagonist β2-agonist that is developed for chronic obstructive pulmonary disease (COPD). The drug has successfully completed phase II clinical trials with clinically significant improvements in lung function. No new or unexpected safety signals were observed in this COPD population. The conclusion from the trial was following that batefenterol 300 µg might represent the optimal dose for Phase III studies.
Status:
Investigational
Source:
NCT01370655: Phase 1 Interventional Completed Hypertension
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-7145 is a piperazine derivative patented by Merck Sharp & Dohme Corporation as the renal outer medullary potassium channel inhibitor useful for the treatment of hypertension and heart failure. In preclinical studies, MK-7145 shows selectivity against other cardiac ion channels such as Cav1.2, Nav1.5, and Kir2.1, Kir2.3, Kir4.1, or Kir7.1. In 2011 MK-7145 was studied in phase I clinical trials but no further development reports were published.
Status:
Investigational
Source:
NCT00519376: Phase 2 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
VILANTEROL α-PHENYL CINNAMATE (GW642444H), originally developed by GlaxoSmithKline, is a long-acting β2 adrenoceptor agonist for once daily treatment of COPD and asthma. Phase III clinical trials are ongoing. GW642444H is Vilanterol a-phenylcinnimate salt. In clinical studies the study drug may been given as a dry powder in the form of either the ‘H’ salt (with the excipient lactose), or in the form of the ‘M’ salt (with the excipients lactose and cellobiose octaacetate). Its pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with relaxation of bronchial smooth muscle and inhibition of release of hypersensitivity mediators from mast cells in the lungs.
